FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
Posted
Vandana Singh (via Benzinga)
The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals' azenosertib studies. Zentalis plans to work with trial investigators to continue development while presenting additional data later this year.
read more
Biotech,
Briefs,
Equities,
News,
Stories That Matter,
why it's moving,
ZNTL,
Health Care,
FDA,
Movers,
Trading Ideas,
General,
ZNTL,
News,
Biotech,
Equities,
Health Care,
FDA,
Movers,
Trading Ideas,
General,
Benzinga
